Filing Flows › Medical Properties Trust (MPT) › Stock forecast & fair value
Medical Properties Trust (MPT) stock forecast and fair value
Medical Properties Trust (MPT) trades at $3.14. 6 analysts' median price target is $3.88 (+23%), from $2.00 to $5.00. Across 12 valuation methods the middle fair value is $3.65 (+16%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | −$8.73 | −$0.72 | $3.70 | -123% |
| EV/Sales vs peers, weighted | −$0.89 | $4.20 | $7.96 | +34% |
| EV/Sales vs peers, matched | −$8.72 | −$0.74 | $3.33 | -123% |
| Residual income | $4.31 | $4.47 | $4.64 | +42% |
| P/FFO vs REIT peers | $2.82 | $3.38 | $4.81 | +7% |
| P/FFO vs REIT peers, weighted | $3.32 | $4.29 | $6.13 | +37% |
| Analysts' price targets | $2.00 | $3.67 | $5.00 | +17% |
| Owner earnings capitalized | $3.21 | $3.65 | $4.23 | +16% |
| Shareholder yield (dividends + buybacks) | $0.49 | $0.55 | $0.64 | -82% |
| Stage-weighted value (reit) | $3.29 | $3.72 | $4.76 | +18% |
Medical Properties Trust's latest quarter
Medical Properties Trust, Q3 2026: revenue $250M (+5% year over year), operating margin 84.8%, net earnings $202M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for MPT stock?
The median of 6 analysts' 12-month targets is $3.88, +23% from $3.14; the range is $2.00 to $5.00. The average rating is hold.
What is Medical Properties Trust's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$1.93 and $4.47, with a middle value of $3.65 against a price of $3.14. Each method's assumptions are on the page.
Does Medical Properties Trust usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is MPT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.